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ABSTRACT
Background: Muscular strength deficits are a common morbid-
ity following treatment for breast cancer. Accurate assessment 
of strength and muscular endurance following breast cancer 
treatments is essential in identifying deficits and planning 
rehabilitation strategies. Purpose: The purpose of this system-
atic review was to identify strength and muscular endurance 
outcome measures for use with women treated for breast cancer 
that possess strong psychometric properties and are clinically 
useful. Methods: Multiple electronic databases were searched 
between February and June 2013. Included studies of tools used 
to assess strength and muscular endurance met the following 
criteria: reported psychometric properties, clinically feasible 
methods, adults (preferably female), and published in the English 
language. Each outcome measure was reviewed independently 
and rated by two reviewers separately. A single Cancer EDGE 
Task Force Outcome Measure Rating Form was completed for 
each category of strength or endurance assessment, and a recom-
mendation was made using the 4-point Breast Cancer EDGE 
Task Force Rating Scale. Results: Of the original 874 articles 
found, 22 were included in this review. Hand Grip Strength and 
Hand Held Dynamometry were rated 3, recommended for clini-
cal use. Manual muscle test and one repetition maximum were 
rated 2B, unable to recommend at this time. Muscular endur-
ance testing was rated 2A, unable to recommend at this time. 
Conclusions: Utilizing objective dynamometry for hand grip and 
muscle strength testing provides precise measurement to assess 
baseline status and monitor change among women treated for 
breast cancer.  
Key Words: psychometrics, dynamometry, outcome assessment, 
breast neoplasms
INTRODUCTION
Upper limb muscular weakness and diminished muscular 
endurance are common deficits among breast cancer survivors 
(BCS) after treatment and can result in upper limb dysfunction.1 
Strength deficits of 20% in scapular and gleno-humeral shoulder 
musculature were reported among 24 women with breast cancer 
within the first 6 months after treatment,2 and in a sample of 75 
BCS, shoulder musculature strength deficits ranging from 7% 
to 18% persisted more than a year after treatment.3 Strength 
losses may stem from one or more aspects of cancer treatment. 
Surgical cancer treatment often involves resecting peripheral 
nerves that may result in nerve injury (such as stinger injuries), 
removing muscles (such as in a total radical mastectomy), or 
using muscles for reconstruction [such as in a transverse rectus 
abdominis myocutaneous (TRAM) flap]. All of these procedures 
may alter muscle action. Chemotherapy treatment  may result in 
chemotherapy induced peripheral neuropathy (CIPN), which can 
include distal weakness and sensory loss4 increasing the risk for 
balance impairment or falls.5 Effects on muscle fibers may be 
cumulative depending on the treatments each BCS undergoes 
causing further loss of upper quadrant strength. Strength deficits 
can impact functional abilities of the upper limb in daily home 
and work activities,6 ultimately adversely affecting quality of life. 
Muscular endurance deficits are also documented after 
treatment for breast cancer. Muscular endurance is defined as 
the ability to sustain a force over time in order to complete an 
activity. In a study of 214 women with unilateral breast cancer 
diagnosed 6 months prior to data collection, muscular endurance 
measured using the Upper Body Strength and Endurance test, 
was significantly less on the treated side when compared to the 
untreated side.7 These deficits persisted 18 months after surgery 
in 186 BCS.8 Both muscular strength and muscular endurance 
can impair overall upper extremity function among women with 
breast cancer. Accurate documentation of both strength and 
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muscular endurance prior to and following treatments for breast 
cancer aligns with the Prospective Surveillance Model for Breast 
Cancer recommendations to identify early and rehabilitate any 
deficits that develop postoperatively.9
In 2010, the American Physical Therapy Association’s 
(APTA) Oncology Section created the Evaluation Database to 
Guide Effectiveness (EDGE) Task Force to develop recom-
mendations for outcome measures to be used when assessing the 
status of cancer survivors.10 This systematic review continues the 
work of the Oncology Section Breast Cancer EDGE Task Force 
by evaluating the ways in which strength and muscular endur-
ance are measured clinically. Strong psychometric properties of 
outcome measures including reliability, validity, minimal detect-
able change (MDC) and/or minimally clinically important differ-
ence (MCID), are needed to justify clinical use. Tools used to 
measure outcomes should be validated in the population in which 
they are used. For example, a measure used to evaluate a shoul-
der impairment caused by a postsurgical shoulder arthroplasty 
may not be a useful tool for the patient with shoulder impairment 
secondary to breast cancer treatment including surgery. The clini-
cal presentation of the above two patient populations may vary 
with different postoperative precautions, treatment guidelines, 
and treatment progression. In addition to strong psychometric 
properties, clinical utility is an important consideration. Qualities 
of clinical utility include availability of resources, cost, ease of 
use including time necessary to complete testing and clinician 
training, scoring and interpretation, and availability of normative 
data for comparison. An outcome measure may have outstanding 
psychometric properties, however, clinicians ultimately need a 
measure that is easy to administer with the least amount of patient 
and provider burden. The purpose of this systematic review was 
to identify strength and muscular endurance outcome measures 
for use with BCS that possess strong psychometric properties and 
are clinically useful. 
METHODS
Search strategy
The primary search strategy was conducted between 
February and June 2013 using multiple electronic databases, 
including Web of Science, Pubmed/Medline, CINAHL, Ovid, 
Google Scholar, Sports Discus, Cochrane Review, PEDro, and 
Academic Search. Search terms used alone and in combination 
included: strength measure/measurement/test, muscular endur-
ance measure/measurement/test, manual muscle test, psychomet-
ric properties, clinimetrics, dynamometer/dynamometry, power, 
energy, along with the following MESH terms: “Muscle strength 
dynamometer” OR “Muscle Strength” OR “Hand Strength.” 
Studies of tests of muscle strength and muscular endurance had 
to meet the following inclusion criteria: reported psychomet-
ric properties, clinically feasible methods, adults (preferably 
female), and published in the English language. Exclusion criteria 
included non-clinical measures of strength and muscular endur-
ance as well as studies of functional mobility measures (Timed 
Up and Go, Sit to Stand, gait speed, etc). Bibliographic review 
of relevant articles was conducted as well as review of journals 
focusing on orthopedics or fitness measures. The publication 
dates were limited to 1/1/1995 and after, as long as the inclusion 
criteria were met. Studies conducted on participants who had 
breast cancer were preferred; however, if none were available, 
similar populations were considered when evaluating the psycho-
metric properties. Each outcome measure was reviewed inde-
pendently and rated by two reviewers separately. If an outcome 
measure rating was found to be in disagreement between the two 
independent reviewers, the disagreement was resolved by discus-
sion with 4 reviewers until agreement was obtained.
After completion of the literature search, relevant articles 
were classified into 4 strength categories and one additional 
category for muscular endurance. The 4 strength categories 
were:  manual muscle testing (MMT), one-repetition maximum 
(1-RM) testing, hand grip strength (HGS) using dynamometry, 
and hand-held dynamometry (HHD). The categories for strength 
measurement tools were selected based on characteristics of each 
measurement tool described in the available literature.
Data Extraction and Synthesis
Relevant data were extracted and recorded on the Cancer 
EDGE Task Force Outcome Measure Rating Form for each study 
(Appendix).  Relevant data included intra-, inter-, and test-retest 
reliability values, with confidence intervals as available, validity, 
MDC, standard error of measurement (SEM), and MCID. Studies 
were then grouped together into common categories and a single 
Cancer EDGE Task Force Outcome Measure Rating Form was 
completed for each category of strength assessment or muscular 
endurance assessment. Upon completion of the Cancer EDGE 
Task Force Outcome Measure Rating Form, a recommendation 
was made using the 4-point Breast Cancer EDGE Task Force 
Rating Scale (Figure 1).10 Determination of good psychometric 
properties related to reliability was determined by either the 
Intraclass Correlation Coefficient (ICC) or Kappa values (K). The 
ICCs greater than 0.75 are considered good to excellent, 0.5-0.74 
moderate, and below 0.5 considered poor.11 Kappa values greater 
than 80% demonstrated excellent agreement, 61% to 80% 
substantial agreement, 41% to 60% adequate agreement, and less 
than 40% showed poor agreement.11 Validity was assessed by 
ICCs or Pearson Product Correlation Coeffecient (r), and rated 
using the same values noted previously.  Clinical utility was 
assessed using criteria noted earlier (availability of resources, 
cost, ease of use including time necessary to complete testing and 
clinician training, scoring and interpretation, and availability of 
normative data for comparison).
RESULTS
The initial literature search for muscle strength and muscular 
endurance resulted in 874 articles. The assessors reviewed the 
titles and 34 duplicates were removed. The remaining 840 titles 
and abstracts of the articles were then reviewed to identify studies 
that specifically addressed the research purpose. A total of 302 
articles were retrieved and assessed for eligibility. After exclu-
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sions were applied, 21 articles were included in the study. See 
Flow diagram detailing search process (Figure 2).
For the 4 categories assessing strength, 3 articles used MMT, 
4 related to 1-RM testing, 8 to HGS, and 5 for HHD. For the 
category examining muscular endurance, multiple articles were 
excluded from analysis secondary to applying inclusion and 
exclusion criteria, leaving only one article with psychometric 
properties. 
Two measures were given a 3, Recommended, by the Breast 
Cancer EDGE Task Force members and are recommended for 
clinical use: Hand Grip Strength and Hand Held Dynamometry. 
Two other measures: Manual muscle test and 1-RM were scored 
a 2B: Unable to recommend at this time, due to a lack of psycho-
metric support. Muscle endurance was rated a 2A: Unable to 
recommend at this time, due to poor clinical utility.  Furthermore, 
power was measured in these studies rather than the sustained 
force over time necessary to measure endurance. Table 1 lists 
the clinical usefulness of the muscular strength and endurance 
tests.  Table 2 contains the  Task Force ratings and clinical util-
ity comments.  Table 3 details the psychometric properties of the 
clinical measures of strength and muscular endurance. 
DISCUSSION
An accurate and reliable assessment of strength and muscu-
lar endurance is an important component of evaluating the status 
of BCS prior to and following medical treatment in order to 
establish a comprehensive picture of their functional needs and 
goals, and monitor and document progress toward full return to 
function. The Prospective Surveillance Model for Breast Cancer 
relies upon the ability to prospectively monitor the status of BCS 
over time in order to prevent or rehabilitate early those morbidi-
ties that may accompany breast cancer treatments.9 Findings from 
this systematic review indicate that the measurement of strength 
is best performed using objective dynamometry for both hand 
grip and extremity measures. No recommendations for the clini-
cal measurement of muscular endurance can be made at this time.
Strength
Strength is considered the quantification of force output from 
muscular action. Clinical measurement of strength has long been 
performed using the manual muscle test system, ranking strength 
on a 0-5 scale (0 representing no muscular contraction and a 5 
indicating full strength).12 Two primary limitations to using MMT 
confound the effective evaluation of patient status. First, this 
method of evaluating strength is subjective. The tester must make 
assessments of how much force a patient can generate for those 
Figure 2. PRISMA flow of literature search.
4 Highly Recommend
Highly recommended; the outcome has good psychometric properties and good clinical utility; the measure has been 
used in research on individuals with or post breast cancer.
3 Recommend
Recommended; the outcome measure has good psychometric properties and good clinical utility; no published evidence 
that the measure has been applied to research on individuals with or post breast cancer.
2A
Unable to Recommend  
at This Time
Unable to recommend at this time; there is insufficient information to support a recommendation of this outcome 
measure; the measure has been used in research on individuals with or post breast cancer.
2B
Unable to Recommend  
at This Time
Unable to recommend at this time; there is insufficient information to support a recommendation of this outcome 
measure; no published evidence that the measure has been applied to research on individuals with or post breast cancer.
1 Do not Recommend Poor psychometrics &/or poor clinical utility (time, equipment, cost, etc).
Figure 1. Breast Cancer EDGE Task Force Rating Scale.
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grades greater than 3 (antigravity grades of 3+, 4-, and 4), and 
although testers have been shown to be able to make this judg-
ment consistently within a single participant, the differences in 
force exerted by multiple testers of a 3+ for the same participant 
are quite variable.13 Secondly, the ranking of MMT grades is an 
ordinal rather than an interval scale; the difference between a 3 
and a 4 is not necessarily the same as the difference between a 4 
and a 5.  This does not allow the clinician to accurately describe 
strength gains made through rehabilitative measures, and gener-
ally lacks the sensitivity needed to appreciate small gains in 
strength.
Accurate assessment of strength relies upon a unit of measure 
that is intuitively sound. Force is measured by Newtons (N), 
pounds (lb), or kilograms (kg); output on dynamometers is gener-
ally in pounds or kilograms. With a clear objective measurement 
unit, normative data for gender and age can be established. This 
normative data then serves as the basis to make a determination 
about the status of the strength levels in individuals with pathol-
ogy. As such, multiple studies outside the realm of this review 
do provide normative data for hand grip and extremity strength 
using dynamometry. The reader is referred to these sources for 
this information.14-16 Further rationale for the use of dynamometry 
as a sound objective measure of strength is that the unit scale for 
dynamometry is interval, with a consistent amount of change 
between each increment of measure. This type of data allows the 
clinician to monitor change accurately, and with greater sensitiv-
ity to change.
Using HHD to measure strength in a clinical realm is as 
simple as MMT, yet provides a quantification of a maximal 
voluntary isometric contraction. The testing positions to measure 
muscular strength do not differ from MMT positions, yet the 
numerical output of a dynamometer can serve as a basis to 
determine the magnitude of a strength deficit when compared 
to normative values. The standard error of measurement of two 
HHDs examined in this review varies from 4.9-12.5 N.17,18 The 
equivalency between 1 kg or 2.2 lbs is 9.8 N. With a SEM of 
no greater than 12.5 N, the error of measurement is less than 1.3 
kg. Hand grip dynamometers have a standard error of measure 
of 0.77 – 2.3 kg.19,20 These small SEM allow a clinician to be 
confident that change in excess of 1.5 kg is real change. Few 
studies have examined the MDC or MCID for dynamometry, 
but an study investigating the smallest detectable difference, 
which is synonymous with the MDC, found that value to be 3 
kg.17 Clinically meaningful change will vary dependent upon the 
muscle group tested and require the clinical judgment of the prac-
titioner; however, any change in excess of 3 kg can be considered 
real change.
One limitation in the use of HHD is the variability result-
ing from the strength and size of the tester. Researchers have 
reported that differing values can be obtained related to differ-
ing gender, body weight, and grip strength of the tester.21 Use 
of external fixation for the dynamometer can improve the inter-
rater reliability of dynamometry in a clinical setting. Studies 
have investigated different devices including brackets,22-24 or 
Table 1. Clinical Usefulness of Strength and Muscular Endurance Testing Methods
Measure Equipment Needed Cost Ease of Use Scoring/Interpretation Normative Data
MMT No None High Easy Yes*
1-RM No Minimal High Easy Yes
HGS Yes Moderate High Easy Yes
HHD Yes Moderate High Easy Yes
Abbreviations:  MMT, manual muscle test; 1-RM,  one repetition maximum; HGS, hand grip strength; HHD, hand-held dynamometry
*This is based on the rating of a 5 being ‘normal’ strength.
Table 2. Breast Cancer EDGE Task Force Ratings and Clinical Utility of the Strength Measures for Breast Cancer Survivors
Measure
Breast Cancer EDGE Task 
Force Rating
Clinical Utility
Hand Grip Strength 3
Equipment is easy to use clinically and staff training is simple.
Good clinical utility.
Hand-held Dynamometry 3
Easy to use clinically.
Methodology similar to Manual Muscle Testing.
Normative data available.
Good clinical utility.
Muscle Endurance 2A
Not often tested clinically. Isokinetic testing used in one study that is not clinically  
feasible. Power is measured more than muscular endurance.
Manual Muscle Test 2B Highly useful in the clinic but poor psychometric properties do not support use.
1-Repetition Maximum 2B Not often used clinically. Psychometric support is limited.
Rehabilitation Oncology
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Table 3. Psychometric Properties of Strength and Muscular Endurance Methods or Tools
Hand Grip Strength Hand-held Dynamometry
Muscular 
Endurance
Manual Muscle Testing 1-RM
In
tr
a-
te
st
er
 r
el
ia
bi
lit
y
ICC = 0.91 – 0.95 (CI = 0.80-0.96)31 
r 0.82 - 0.9119 
ICC = 0.94 - 0.9832 (healthy)
ICC = 0.87 - 0.9732 (cervical radicu-
lopathy)
ICC = 0.90 – 0.93 (CI = 0.83-0.96)33 
(Jamar)
ICC = 0.95 – 0.96 (CI = 0.91-0.98)33 
(NK)
ICC = 0.97 - 0.99 (CI = 0.90-0.99)34 
(healthy)
ICC = 0.86 – 0.92 (CI = 0.61-0.97)34 
(critically ill) 
ICC = 0.89 – 0.98 (CI = 0.62-
0.99)17 (healthy)
ICC 0.93-0.9835 (older adults)
In
te
r-
ra
te
r 
re
lia
bi
lit
y
r = 0.9919
ICC 0.9832 (healthy)
ICC 0.96 – 0.97 (CI = 0.83-0.99)34 
(healthy)
ICC 0.89 – 0.92 (CI = 0.54-0.97)34 
(critically ill)
ICC = 0.95 - 0.9620
ICC = 0.94 – 0.9836
ICC = 0.77-0.9734 (healthy)
ICC = 0.72 – 0.79 (CI = -0.19-
0.95)34 (healthy)
ICC = 0.62 – 0.71 (CI = -0.21-
0.93)34 (critically ill)
ICC = 0.91 – 0.96 (CI = 0.85-
0.98)37 (critically ill)
ICC = 0.83 (CI = 0.67-
0.91)38
ICC = 0.99 (CI = 0.97-
1.00)39
k = 0.54 (CI = 0.25-0.72)40 
Specific muscles38
ICC = 0.29/0.53 (left/right 
elbow flex)
ICC = 0.53/0.68 (left/right 
shoulder abductor) 
ICC = 0.50/0.61 (left/right 
wrist extension)
1-RM 41 
Lat pull downs,  bench 
press, elbow flexion
 
Males
1-RM: r = 0.89 -  0.98 
40%: r = 0.80 - 0.98
60%: r =  0.79 – 
0.96
80%: r =  0.89 - 0.98
Females
1-RM: r = 0.79 - 0.98
40%: r = 0.80 - 0.96
60%: r = 0.80 - 0.95
80%: r = 0.80 to 0.9
T
es
t-
re
te
st
 r
el
ia
bi
lit
y r = 0.90 (CI = 0.81-0.94)18 
(cancer) 
ICC = 0.90 (cancer)18
ICC = 0.93 (CI = 0.47-0.98)34 
(healthy)
ICC = 0.42 – 0.82 (CI = 
-0.54-0.94)34(critically ill)
r = 0.9542 (males)
r = 0.9242 (females)
SE
M
2.2-2.3#19
1.68-2.29#20
10.6 N (NK dynamometer; 
elbow extension)18
4.9 – 12.5N J-Tech Powertrack 
2  (7 UE muscle tests) 17
V
al
id
it
y
of MicroFet compared to Jamar
ICC = 0.97 – 0.99 (CI 0.93-1.00)31
as a measure of function
Fatigue/pain/mood state/UE ROM/
function: ρ = 0.22 - 0.5343
as a measure of functional mobility
r = 0.61-0.8436 (TUG)
r = 0.41-0.6136 (Gait Speed)
Concurrent Validity
r = 0.8642 (males)
r = 0.7942 (females)
Abbreviations: ICC, intraclass correlation coefficient;  r, Pearson’s Coefficient Correlation; CI, confidence interval; SEM, standard error of measurement; #, pounds; 
UE, upper extremity; ROM, range of motion; TUG, timed up and go; r, Pearson’s Coefficient Correlation; CI, confidence interval; ICC, intraclass correlation coefficient; 
SEM, standard error of measurement; SDD, standard deviation of difference; UE, upper extremity; N, newtons
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straps.25,26 Mobilization belts are readily available in clinics, and 
when strapped around the dynamometer and fixed opposite to the 
direction of force, provide a consistent resistance for maximal 
voluntary contractions regardless of the tester. Another limitation 
of the use of HHD and HGS among women diagnosed with breast 
cancer is that these studies have not investigated psychometric 
properties in this population. Reliability and validity estimates, 
nor MCIDs, have been established for use in women with breast 
cancer.
Muscular Endurance
Muscular endurance, the ability to sustain force output over 
time, is seldom assessed in a clinical setting.  This lack of assess-
ment is largely due to a lack of established reliable and valid 
clinical methods to perform such testing. Most studies in strength 
and conditioning literature use some percentage of 1-RM to 
determine the load, and test endurance using a repetition to fail-
ure activity. The number of completed repetitions, then, provides 
information about the level of endurance. Utilizing 40% to 60% 
of a maximum resistance in a repeated fashion is purported to 
increase muscular endurance.27 The usefulness of this method is 
the ability to establish a baseline measure, perform an interven-
tion aimed at increasing endurance through exercise at 40% to 
60% of 1-RM, and then retesting to determine the change in the 
number of repetitions to failure. The limitation of this methodol-
ogy is that normative data for age, gender, and muscle group is 
difficult to establish, as the number of repetitions to failure is 
largely dependent upon the muscle mass of the individual.28
The literature search for this review revealed two studies 
examining muscular endurance in the breast cancer population. 
Both studies used a repetition to failure activity; however, they 
also present methodological limitations. One study of 40 BCS 
within the first 6 months after diagnosis measured endurance 
in the typical repetition to failure count, using 90% of 1-RM 
activity for activities for shoulder flexion, extension, protraction, 
and retraction comparing the involved limb to the noninvolved 
limb.29 Results of the study did not reveal any significant differ-
ences between limbs except greater muscular endurance on the 
involved limb for shoulder flexion.29 The limitation in this study 
is the use of 90% 1-RM, which is in excess of the recommended 
40% to 60% 1-RM by the American College of Sports Medicine 
(ACSM), and by using 90% 1-RM, the musculature recruited for 
the activity was likely more type Type II anaerobic fast twitch 
fibers. Endurance activities typically recruit Type I aerobic slow 
twitch fibers. The second study examining 211 unilateral BCS 6 
months after diagnosis did show a statistically significant differ-
ence in muscular endurance between involved and noninvolved 
limbs (p ≤ 0.05) using a novel test of muscular endurance called 
the Upper Body Strength and Endurance (UBSE) test.7 In this 
test, participants repeatedly lifted an incrementally increas-
ing amount of resistance until failure; progression was based 
on 30 successfully completed repetitions at one weight before 
increasing the weight by 0.5 kg; the last weight lifted at failure 
was recorded for analysis.7 This test used the repetition to failure 
endpoint to measure muscular endurance, but instead of a fixed 
percentage of 1-RM, used a progressively increasing resistance. 
This test does show some potential to be clinically useful but 
can be time-consuming to perform (15-20 minutes depending 
on the level of endurance). Additionally, this test has minimal 
psychometric testing results as it only reports low correlation 
with self-reported arm function using the Disabilities of the Arm, 
Shoulder, and Hand (DASH) (r=-0.26), and has no reported reli-
ability, MDC, or MCID testing. Further refinements in muscular 
endurance testing are needed. 
Isokinetic dynamometry offers a more reliable and valid 
method to measure muscular endurance. In a study of 36 healthy 
participants, Roy et al30 tested an upper extremity endurance 
protocol using a Biodex stationary dynamometer, measuring 
maximal voluntary isometric contraction (MVIC) levels pre- and 
post-endurance activity. The results of this study indicated a statis-
tically significant decline in MVIC after the endurance activity, 
with a good test-retest reliability reported (ICC = 0.84).30 These 
findings suggest that rather than measuring repetitions to failure 
as a unit to quantify endurance, perhaps measuring MVIC pre- 
and post-activity may provide a more reliable and valid method to 
measure endurance. This method is limited in its scope of use as 
most clinics lack this expensive piece of equipment, but suggests 
that MVIC may be useful in developing a clinically feasible test 
for muscular endurance. 
This systematic review was unable to recommend any clini-
cal methods to measure muscular endurance. Further research 
establishing a standardized, reliable, and valid method of measur-
ing muscular endurance is necessary. This clinical method should 
employ the guiding principles of 40% to 60% maximum resis-
tance over a time period, have some quantifiable but reliable 
normative unit of measure, and must be responsive enough to 
detect differences between healthy and injured tissue.
CONCLUSION
Precise strength and muscular endurance measurement allow 
the clinician to accurately identify impairments in body structures 
that may impact activity and participation. Accurate assessment 
is integral for effective prospective surveillance for cancer survi-
vors. Utilizing objective dynamometry for hand grip and muscle 
strength testing provides precise measurement to establish status 
and monitor change. Further research is necessary to devise a 
muscular endurance test for clinical use as well as studies involv-
ing BCS.
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Is this tool appropriate for individual patient decision-making?  Yes  _____     No  _____ 
 
(available MDC, MCID, Likelihood ratios?) 
 
Comments: 
 
 
 
 
 
 
 
 
Availability: 
● Score Sheets:  
_____ Public Domain     _____Available but copyrighted    _____Unavailable 
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